3.560USD+1.14%Mkt Cap: 393.62M USDP/E: —Last update: 2026-05-22
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targ…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap393.62M USD
Enterprise Value211.97M USD
Revenue (TTM)34.86M USD
Gross Profit25.88M USD
Net Income (TTM)-104.99M USD
Revenue/Share0.3600 USD
Last Price3.560 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.04
PEG—
EV/EBITDA-2.10
EV/Revenue6.08
P/S11.16
P/B1.56
EPS (TTM)-1.10
EPS (Forward)-1.16
52W Range
1.21086% of range3.950
52W High3.950 USD
52W Low1.210 USD
Profitability
Gross Margin74.25%
Oper. Margin-451.64%
EBITDA Margin-290.30%
Profit Margin-292.08%
ROE-40.92%
ROA-29.24%
Growth
Revenue Growth-15.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-98.69M USD
CapEx (TTM)607.00K USD
FCF Margin-144.96%
FCF Yield-12.84%
Net Debt-177.22M USD
Net Debt/EBITDA1.75
Balance Sheet
Debt/Equity0.23
Current Ratio9.01
Quick Ratio8.76
Book Value/Sh2.252 USD
Cash/Share2.131 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)11.57 USD
Target Range6.000 USD – 30.00 USD
# Analysts7
Ownership
Shares Out.110.57M
Float79.64M
Insiders1.13%
Institutions76.66%
Short Interest
Short Ratio7.1d
Short % Float19.24%
Short % Out.19.11%
Shares Short21.06M
Short (prev mo.)16.16M
Technical
SMA 502.889 (+23.2%)
SMA 2002.526 (+40.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.76M
Avg Vol (10d)3.41M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—